In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axovan AG

Division of Johnson & Johnson
www.axovan.com

Latest From Axovan AG

Working Around Pre-Emption Rights

Europe's pre-emption rights significantly hamper biotech fundraising. But since they're unlikely to go away, European firms are having to find clever ways around them.
BioPharmaceutical Business Strategies

Actelion/Axovan: Acquisition Through Earnout

Acquiring compatriot Axovan was Actelion's only option to access Phase II endothelin receptor antagonist (ERA) clazosentan; a licensing deal would have left Axovan with too little to remain a standalone company. But the CHF 252 million ($191 million) deal still makes sense for Actelion: the company's initial financial exposure is just CHF 40 million, with most of the remaining deal value linked to milestones. Actelion gains access to a late-stage compound it knows well, that fits perfectly within its own ERA-focused portfolio. Furthermore, it beefs up its R&D and bolsters its preclinical pipeline, all for little more than it would have had to pay for clazosentan alone. Axovan puts its lead compound in the hands of a partner with a proven track record in ERA development and commercialization.
BioPharmaceutical Europe

Recent Dealmaking (11/2003)

Summarizing the month in European dealmaking.

Biolipox AB

Founded in June 2000 by two professors from Sweden's Karolinska Institute, Biolipox AB is focusing on the role of arachidonic acid in inflammation, and looking to develop an improved family of respiratory and anti-inflammatory drugs.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Johnson & Johnson
  • Senior Management
  • Philippe Dro, MD, CEO
  • Contact Info
  • Axovan AG
    Phone: (41) 61 487 76 76
    Gewerbestrasse 16
    Allschwil, 4132
    Switzerland
UsernamePublicRestriction

Register